Literature DB >> 26006198

Rectal indomethacin for the prevention of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials.

Na Shi1, Lihui Deng, Kiran Altaf, Wei Huang, Ping Xue, Qing Xia.   

Abstract

BACKGROUND/AIMS: This meta-analysis was undertaken to evaluate the effect of rectal indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis.
MATERIALS AND METHODS: Major databases including Embase, Medline, Science Citation Index Expanded, Pubmed and the Cochrane Central Register of Controlled Trials, were searched to identify all relevant studies from January 1960 to July 2013. Randomized controlled trials (RCTs) comparing prophylactic use of rectal indomethacin versus placebo were included. Risk ratio (RR) with 95% confidence interval (CI) was calculated using fixed- or random-effect models.
RESULTS: Three studies met the inclusion criteria and were included in the final analyses. The overall incidence of post-ERCP pancreatitis (PEP) was significantly decreased by prophylactic rectal indomethacin compared with the placebo (RR=0.51; 95% CI=0.37-0.70). The pooled incidence of moderate to severe pancreatitis was also decreased by rectal indomethacin prophylaxis (RR=0.43; 95% CI=0.23-0.80).
CONCLUSION: Rectal indomethacin can reduce the overall incidence and the severity of PEP.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26006198     DOI: 10.5152/tjg.2015.6000

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  5 in total

1.  Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.

Authors:  Fariborz Mansour-Ghanaei; Farahnaz Joukar; Zahra Taherzadeh; Homayoon Sokhanvar; Tolou Hasandokht
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 2.  How to select patients and timing for rectal indomethacin to prevent post-ERCP pancreatitis: a systematic review and meta-analysis.

Authors:  Jianhua Wan; Yuping Ren; Zhenhua Zhu; Liang Xia; Nonghua Lu
Journal:  BMC Gastroenterol       Date:  2017-03-15       Impact factor: 3.067

3.  Epinephrine in the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Preliminary Study.

Authors:  Behzad Hatami; Seyed Mohammad Hossein Kashfi; Mohammad Abbasinazari; Ehsan Nazemalhosseini Mojarad; Mohammad Amin Pourhoseingholi; Mohammad Reza Zali; Amir Houshang Mohammad Alizadeh
Journal:  Case Rep Gastroenterol       Date:  2018-04-13

4.  Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial.

Authors:  Yang-Yang Qian; Hui Chen; Xin-Ying Tang; Xi Jiang; Wei Qian; Wen-Bin Zou; Lei Xin; Bo Li; Yan-Fen Qi; Liang-Hao Hu; Duo-Wu Zou; Zhen-Dong Jin; Dong Wang; Yi-Qi Du; Luo-Wei Wang; Feng Liu; Zhao-Shen Li; Zhuan Liao
Journal:  Trials       Date:  2017-11-02       Impact factor: 2.279

5.  Rectal Indomethacin Is Protective against Pancreatitis after Endoscopic Retrograde Cholangiopancreatography: Systematic Review and Meta-Analysis.

Authors:  Xingkang He; Wenfang Zheng; Yue Ding; Xia Tang; Jianmin Si; Lei-Min Sun
Journal:  Gastroenterol Res Pract       Date:  2018-05-09       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.